Molecular Breast Imaging Has Outstanding Sensitivity for the Diagnosis of Invasive Lobular Carcinoma
NEWPORT NEWS, Va., July 16, 2015 /PRNewswire/ -- Molecular Breast Imaging (MBI/BSGI) has been proven to be a highly sensitive imaging technique for the diagnosis of invasive lobular carcinoma (ILC), a difficult to diagnose breast cancer. According to a recent publication in the Journal of the American Medical Association Surgery, physicians at the Legacy Cancer Institute in Portland, Oregon, reported a sensitivity of 88.9% for BSGI in diagnosing ILC disease.
This study was a retrospective review of a prospectively maintained imaging registry at the institution in the course of 6 years. The analysis was conducted with almost 700 patients who underwent the BSGI procedure, which to date makes it the largest pool of data on molecular imaging of ILCs. The results show that BSGI has a slightly higher sensitivity for the detection of ILCs than for the detection of invasive ductal carcinomas (IDCs), while the specificities for both diseases are comparable. BSGI was also reported to detect additional cancers in patients with ILC. BSGI was found to have advantages over MRI as it is easier to interpret, better tolerated by patients and much less costly. The group of physicians concluded that BSGI has high sensitivity and specificity and is an excellent adjunctive imaging tool for patients with newly diagnosed ILCs.
The MBI for the study was conducted using a Dilon Molecular Imaging System, a high-resolution, small field-of-view gamma camera, optimized to perform MBI. With MBI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding tissue and generally appear as "hot spots" on the MBI image.
About Dilon Dilon Technologies® Inc. strives to improve the quality of life by providing a wide range of innovative medical solutions that benefit patients around the world. Dilon is a leader in diagnostic imaging with the Dilon Molecular Imaging Systems, high-resolution, small field-of-view general-use imaging cameras, optimized to perform Molecular Breast Imaging (MBI/BSGI) and localization for MBI-guided breast biopsy. Dilon's cornerstone surgical imaging products, the Navigator® Probes, are one of the most widely used gamma probes for cancer surgery in the marketplace. The gamma probes offer a revolutionary upgrade option for 3D Tumor Imaging and Navigation with SurgicEye's declipseSPECT camera. Dilon is the exclusive international distributor of Digirad's Cardius® cardiac and ergo™ general molecular imaging cameras that provide outstanding image quality and increased patient comfort with a compact, open design. For more information visit www.dilon.com
Media contact: Pjerin Luli
P: 757-269-4910
E: [email protected]
Logo - http://photos.prnewswire.com/prnh/20140106/PH40697LOGO
SOURCE Dilon Technologies, Inc.
Share this article